Search Results - "Kazmi, Abiha"

The Use of Single-Cell RNA-Sequencing and Spatial Transcriptomics in Understanding the Pathogenesis and Treatment of Skin Diseases by Houser, Aubrey E., Kazmi, Abiha, Nair, Arjun K., Ji, Andrew L.

“…The development of multiomic profiling tools has rapidly expanded in recent years, along with their use in profiling skin tissues in various contexts,…”
Get full text

Double PIK3CA mutations in cis increase oncogenicity and sensitivity to PI3Kα inhibitors by Vasan, Neil, Razavi, Pedram, Johnson, Jared L, Shao, Hong, Shah, Hardik, Antoine, Alesia, Ladewig, Erik, Gorelick, Alexander, Lin, Ting-Yu, Toska, Eneda, Xu, Guotai, Kazmi, Abiha, Chang, Matthew T, Taylor, Barry S, Dickler, Maura N, Jhaveri, Komal, Chandarlapaty, Sarat, Rabadan, Raul, Reznik, Ed, Smith, Melissa L, Sebra, Robert, Schimmoller, Frauke, Wilson, Timothy R, Friedman, Lori S, Cantley, Lewis C, Scaltriti, Maurizio, Baselga, José

“…Activating mutations in are frequent in human breast cancer, and phosphoinositide 3-kinase alpha (PI3Kα) inhibitors have been approved for therapy. To…”
Get full text

Abstract PO-022: Community-driven recommendations for a culturally and contextually tailored HPV campaign for Arab and Mexican communities in Brooklyn by Chebli, Perla, Sifuentes, Sonia, Foster, Victoria, Yusuf, Yousra, Kazmi, Abiha, Idris, Sally, Trinh-Shevrin, Chau, Kwon, Simona

“…Purpose. Uneven language access in policy implementation perpetuates health disparity for limited English proficient populations. This study engages Arab and…”
Get full text

Abstract NG16: Double PIK3CA mutations in cis increase oncogenicity and sensitivity to PI3Kα inhibitors by Vasan, Neil, Razavi, Pedram, Johnson, Jared L., Shao, Hong, Shah, Hardik, Antoine, Alesia, Ladewig, Erik, Gorelick, Alexander, Lin, Ting-Yu, Toska, Eneda, Xu, Guotai, Kazmi, Abiha, Chang, Matthew T., Taylor, Barry S., Dickler, Maura N., Jhaveri, Komal, Chandarlapaty, Sarat, Rabadan, Raul, Reznik, Ed, Smith, Melissa L., Sebra, Robert, Schimmoller, Frauke, Wilson, Timothy R., Friedman, Lori S., Cantley, Lewis C., Scaltriti, Maurizio, Baselga, Jose

“…PIK3CA is the most frequently mutated oncogene across all human cancers, and codes for p110α, the catalytic subunit of the PI3K complex. PI3K catalyzes the…”
Get full text

Abstract P3-03-01: Double PIK3CA mutations in cis drive oncogene addiction and enhance sensitivity to PI3K alpha inhibitors in breast cancer by Vasan, Neil, Razavi, Pedram, Johnson, Jared L, Shao, Hong, Wilson, Timothy, Schimmoller, Frauke, Shah, Hardik, Antoine, Alesia, Ladewig, Erik, Gorelick, Alexander, Lin, Ting-Yu, Toska, Eneda, Xu, Guotai, Kazmi, Abiha, Chang, Matthew T, Taylor, Barry S., Dickler, Maura N., Jhaveri, Komal, Chandarlapaty, Sarat, Rabadan, Raul, Reznik, Ed, Smith, Melissa L, Sebra, Robert, Friedman, Lori, Cantley, Lewis C, Scaltriti, Maurizio, Baselga, José

“…Activating mutations in PIK3CA, the gene coding for the catalytic subunit (p110α) of phosphoinositide-3-kinase (PI3K), are the most frequent oncogenic…”
Get full text

Abstract A21: Compound PIK3CA mutations support a mutational dose-response model for oncogene activation and response to PI3K inhibitor targeted therapy in breast cancer by Vasan, Neil, Johnson, Jared, Shao, Hong, Razavi, Pedram, Gorelick, Alexander, Ladewig, Erik, Antoine, Alesia, Shah, Hardik, Toska, Eneda, Xu, Guotai, Kazmi, Abiha, Taylor, Barry, Jhaveri, Komal, Dickler, Maura, de Stanchina, Elisa, Reznik, Eduard, Rabadan, Raul, Smith, Melissa, Sebra, Robert, Cantley, Lewis, Scaltriti, Maurizio, Baselga, Jose

“…PIK3CA mutations represent the most frequent oncogenic driver lesion found across all human cancers. Given that single PIK3CA mutations are a predictive…”
Get full text

Abstract 3917: Double PIK3CA mutations in cis enhance oncogene activation and sensitivity to PI3K alpha inhibitors in breast cancer by Vasan, Neil, Razavi, Pedram, Johnson, Jared, Shao, Hong, Shah, Hardik, Antoine, Alesia, Ladewig, Erik, Gorelick, Alexander, Toska, Eneda, Xu, Guotai, Kazmi, Abiha, Chang, Matthew T., Taylor, Barry S., Dickler, Maura N., Jhaveri, Komal, Rabadan, Raul, Reznik, Ed, Smith, Melissa L., Sebra, Robert, Cantley, Lewis C., Scaltriti, Maurizio, Baselga, Jose

“…Activating mutations in PIK3CA, the gene coding for the catalytic subunit (p110α) of phosphoinositide 3-kinase (PI3K), are the most frequent oncogenic…”
Get full text